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Abstract The opioid receptors /~, 5 and • have recently been 
cloned. Here we show that ~-agonists inhibit adenylyl cyclase 
activity in Chinese hamster ovary cells stably transfected with rat 
K-opioid receptor cDNA. Chronic exposure of the cells to K- 
agonists did not lead to significant desensitization of the capacity 
of the agonists to inhibit adenylyl cyclase. On the other hand, 
withdrawal of the agonist following the chronic treatment led to 
the phenomenon of supersensitivity ('overshoot') of adenylyl 
cyclase activity. Both the inhibition of adenylyl cyclase activity 
by the acute opioid treatment and the chronic agonist-induced 
supersensitivity are pertussis toxin sensitive, demonstrating in- 
volvement of GJGo proteins in both processes. 
Key words: Opioid receptor; Forskolin; Adenylyl cyclase; 
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1. Introduction 
Pharmacological studies have defined three types of opioid 
receptors, termed p, g and ~, that differ in their affinity for 
various opioid ligands and in their distribution i  the nervous 
system [1]. Activation of all three types of opioid receptors leads 
to inhibition of adenylyl cyclase (AC) activity, and this effect 
is mediated through pertussis toxin (PTX)-sensitive GTP-bind- 
ing proteins (G proteins) [2,3]. 
Chronic activation of opioid receptors in NG108-15 neuro- 
blastoma x glioma cell line (containing g-receptors), as well as 
in the human neuroblastoma SH-SY5Y (containing mainly p- 
receptors and some g-receptors), followed by the withdrawal 
of the opioid agonist, was shown to lead to AC supersensitivity 
('overshoot') [4-8]. It has been suggested that this phenomenon 
represents a possible cellular adaptation mechanism associated 
with chronic opioid exposure. However, due to the absence of 
cell lines containing x-opioid receptors there was no definite 
information regarding the exact role of acute and chronic acti- 
vation of x-receptors and of the effect of agonist withdrawal 
on AC activity. 
The three types of opioid receptors have recently been cloned 
[9,10]. They are all members of the seven-transmembrane do- 
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main G protein-coupled receptor superfamily. The availability 
of cDNAs for the opioid receptors allows molecular studies of 
their binding and signal transduction properties. We have sta- 
bly transfected Chinese hamster ovary (CHO) cells with the rat 
K-receptor cDNA and found that x-opioid agonists markedly 
inhibit he forskolin-stimulated AC activity. The removal of the 
opioid agonist following chronic x-opioid treatment leads to a 
large increase in the level of the forskolin-induced cAMP accu- 
mulation in the cells. These results demonstrate, for the first 
time, that the 'overshoot' phenomenon can be observed for 
x-opioid receptors and can be obtained with non-neuronal 
cells. 
2. Materials and methods 
2.1. Mater&& 
[3H-2]Adenine was purchased from Rotem Industries (Be'er Sheba, 
Israel). [15,16(n)-3H]Diprenorphine (36 Ci/mmol) was purchased from 
Amersham (Bukinghamshire, UK). Opioid ligands were obtained from 
Research Biochemical International (Natick, MA) and from the Na- 
tional Institute on Drug Abuse, Research Technology Branch (Rock- 
ville, MD). 1-Methyl-3-isobutylxanthine (IBMX), forskolin, PTX and 
cAMP were from Sigma (St. Louis, MO). Geneticin (G418) and tissue 
culture reagents were from Gibco BRL (Bethesda, MD). 
2.2. Cell transfection and culture 
CHO-K1 cells were transfected with rat x-receptor cDNA inserted 
into the mammalian expression vector pCMV-neo [11], using the cal- 
cium phosphate method, as previously described [12]. Clones resistant 
to G418 (1 mg/ml) were isolated and analyzed for their capacity to bind 
[3H]diprenorphine. TheCHO-x-opioid receptor cell lines were cultured 
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal calf serum, 2mM glutamine, non-essential amino acids, 0.2 
mg/ml G418, 100 U/ml penicillin and 100/ag/ml streptomycin i a 
humidified atmosphere consisting of 5% CO2 and 95% air at 37°C. 
2.3. Opioid receptor-binding assays 
Cell homogenates (75 200/ag protein) were incubated for 1 h at 25°C 
with 0.01-3 nM [3H]diprenorphine or [3H]U69593, ina final volume of 
200/al of 50 mM Tris-HC1 (pH 7.4). Bound ligand was separated by 
filtration through Whatman GF/B glass filters using the Brandel cell 
harvester (Gaithersburg, MD) and the radioactivity determined by 
liquid scintillation. K a and Bma X values were calculated by Scatchard 
analysis following subtraction ofnon-specific binding, measured inthe 
presence of 10/aM U69593. 
2.4. A C assay 
This assay was performed essentially asdescribed [13]. In brief, cells 
cultured in 24-well plates (250,000 cells/well) were incubated for 4 h 
with 0.25 ml/well of fresh growth medium containing 5 /aCi/ml of 
[3H]adenine. This medium was replaced with 0.5 ml/well of DMEM 
containing 20 mM HEPES (pH 7.4), 0.1 mM IBMX and 1/aM fors- 
kolin. After 10 min at 37°C, the medium was removed and the reaction 
terminated with 1 ml of 2.5% perchloric acid containing 0.1 mM of 
unlabeled cAME Opioids were added either together with the forskolin 
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for the 10-rain incubation period (acute xposure) or together with the 
[3H]adenine for a 4-h incubation (chronic treatment). The chronic 
opioid exposure did not affect the uptake of [3H]adenine by the cells. 
After 15 min with perchloric acid at 4°C, volumes of 0.9 ml were 
neutralized with 100/21 of a mixture of 3.8 M KOH and 0.16 M K2CO 3. 
Aliquots of 0.9 ml of the supernatants were applied to a two-step 
column separation procedure as previously described [14]. The 
[3H]cAMP was eluted into scintillation vials and counted. In experi- 
ments utilizing PTX, it was added to the cultures 20 h before adding 
[3H]adenine and was replenished upon the addition of [3H]adenine. 
3. Results 
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3.1. Characterization of  CHO cells expressing ~-opioid 
receptors 
We have transfected CHO-K I  cells and isolated clones ex- 
pressing x-receptors. Two of the clones, CHO-x/5 and CHO-x/  
8, were used for further studies. The Kd value for binding of the 
x-agonist [3H]U69593 to the receptors in these cell lines was 
1.05 + 0.09 nM (n -- 3). The K d values for [3H]diprenorphine 
binding to CHO-x/5 and CHO-x/8 were 0.35 + 0.06 nM (n = 4) 
and 0.61 + 0.03 nM (n = 5), and the Bma x values were 252 + 52 
and 388 + 66 fmol/mg protein, respectively. The application of 
x-opioid agonists to these cells led to a marked inhibition of 
cAMP accumulation. The effect of various opioid ligands on 
the forskolin-stimulated cAMP accumulation i  CHO-K/8 cell 
line is illustrated in Fig. 1. Similar results were obtained with 
CHO-x/5. The non-selective opioid agonist etorphine and the 
x-selective opioid agonists (-)U50488, U69593 and dynorphin- 
CON U69 (-)US0 (+)U50 n-BNi 
Pz~ 
n-BNI added 
ETO DAMGE DYN 
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Fig. 1. Effect of opioids on forskolin-stimulated cAMP accumulation 
in CHO cells transfected with l¢-opioid receptors. Agonists were used 
at 10 nM, and nor-BNI was used at 100 nM. Control (CON); etorphine 
(ETO); dynorphin (DYN); U69593 (U69); U50488 (U50). The back- 
ground level (210 cpm) was subtracted from all values. The value of 
forskolin-stimulated AC in the absence of opioids was defined as 100% 
(750 cpm). The data show a representative experiment performed with 
the CHO-t¢/8 cell line. Similar results were obtained with CHO-x/5. 
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2.5. Statistical analysis 
Data were analyzed using Student's t-test. Binding parameters 
(Kd and Bm~x values) were determined by Scatchard plot analysis. AC 
inhibition curves were generated with the Sigma Plot 4.11 computer 
program (Jandel Scientific, Corta Madera, CA) and the ECs0 were 
determined, using an equation from the ALLFIT program [15]; n rep- 
resents the number of experiments. 
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Fig. 2. Effects of acute and chronic x-agonist exposure on cAMP 
accumulation i CHO-tc/8 cells. (A) Forskolin-stimulated cAMP accu- 
mulation in cells incubated for either 10 min (e) or 4 h (v) with the 
indicated concentrations of U69593. The ECs0 for cAMP inhibition did 
not significantly differ for the acute (7.8 + 1.8 nM) and chronic 
(4.0 + 2.1 nM) U69593-treated cells. The incubation for 10 min was 
repeated in cells (©) pretreated with PTX (100 ng/ml, 24 h). (B) Fors- 
kolin-stimulated cAMP accumulation i cells treated chronically (4 h) 
with the indicated concentration of U69593, to which 1 ltM naloxone 
was added 10 min prior to the assay (m). The ECs0 for cAMP stimula- 
tion was 203 + 37 nM. Data are the mean + S.E.M. of three experi- 
ments. 
AM3, were very effective in inhibiting cAMP accumulation in 
the x-transfected CHO cells, reaching levels of 75-85% inhibi- 
tion with 10 nM of added opioid agonists. In agreement with 
the known pharmacology of the x-receptors, the inactive ster- 
eoisomer (+)U50488 and the /x-selective opioid agonist 
DAMGE were not active. Moreover, the x-opioid antagonist 
nor-binaltrophimine (nor-BNl) had no effect by itself and 
blocked the inhibitory effects of x-agonists on cAMP accumu- 
lation in the cells. 
The inhibition of the forskolin-stimulated cAMP accumula- 
tion by U69593 was dose dependent (Fig. 2A) with an ECs0 of 
7.8 + 1.8 nM. The maximal evel of inhibition (i.e. 90-95% of 
the forskolin-stimulated cAMP accumulation) was obtained 
with 0.1-1/xM of U69593. Pretreatment of the cells with PTX 
completely blocked the inhibitory effects of opioids on AC, 
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Fig. 3. PTX sensitivity ofthe forskolin-stimulated cAMP accumulation 
in CHO-x/8 cells following acute or chronic treatments with 1 /.tM 
U69593. Forskolin-stimulated cAMP accumulation was determined in 
control cells (A), or in PTX-pretreated (100 ng/ml, 24 h) cells (B), 
following acute (10 min) or chronic (4 h) treatment with 1/IM U69593. 
Data are the mean + S.E.M. of three xperiments. Significantly differ- 
ent from control cells, *P<0.05 and #P<0.01, respectively. 
indicating the involvement of Gi or Go protein in mediating this 
process. 
3.2. Effect of chronic agonist exposure on AC activity 
CHO-x/8 cells were pretreated for 4 h with the indicated 
concentrations of U69593 and the forskolin-induced AC activ- 
ity was determined. The results how (Fig. 2A) that exposure 
of CHO-x/8 cells to U69593 for 4 h did not affect he capacity 
of U69593 to inhibit he forskolin-stimulated cAMP accumula- 
tion. Both the ECs0 and the maximal inhibition of AC were not 
markedly affected, suggesting that in this transfected CHO cell 
line the opioid receptors did not undergo desensitization fol- 
lowing treatment with the indicated concentrations of U69593. 
In agreement with this result, no reduction in the maximal 
inhibition of the forskolin-stimulated cAMP accumulation was 
observed when the cells were pretreated with 1/.tM U69593 for 
24 h (data not shown). 
A compensatory increase in PGE~- or forskolin-stimulated 
AC activity has been reported following long-term exposure of 
NG108-15 or SH-SY5Y to opioid agonists [4--7]. We examined 
whether a similar effect could also be detected in the CHO cell 
lines stably transfected with x-receptors. For this purpose, cells 
were treated for 4 h with the indicated concentrations of
U69593, and the antagonist naloxone was applied 10 min prior 
to the assay to remove the agonist inhibitory effect on AC 
activity. The results (Fig. 2B) clearly indicate that the with- 
drawal of U69593 following the 4-h chronic treatment induced 
an 'overshoot' in forskolin-stimulated cAMP accumulation, as
compared with control forskolin-stimulated c lls (not treated 
with U69593). Treatment with naloxone alone (without previ- 
ous exposure to opioid agonists) did not influence the forskolin- 
stimulated cAMP accumulation (96 + 4% of control, n = 9) (see 
also Fig. 3). The increase in cAMP accumulation under the 
'withdrawal' conditions proved to be dependent on the agonist 
concentration used in the chronic exposure step, and reached, 
in this experiment, levels as high as 250% above control evels 
(Fig. 2B). The level of overshoot in various experiments, using 
1 /tM U69593 at the chronic step, ranged between 100 and 
440% above control evels. It should be stated that treatment 
with low concentrations of U69593 (e.g. 0.1-3 nM), which were 
sufficient to inhibit accumulation f cAMP (by up to 40%), did 
not induce the overshoot effect. The ECso of the U69593-trig- 
gered naloxone-induced overshoot in cAMP accumulation was 
found to be equivalent to 203 + 37 nM of U69593. 
As shown in Fig. 3, the overshoot effect could also be ob- 
tained by a rapid wash of the agonist, as well as by the addition 
of other antagonists besides naloxone (e.g. 1/tM nor-BNI or 
diprenorphine). Moreover, the combination of a wash with the 
subsequent application of an antagonist was as efficient as 
either wash or antagonist alone. These results demonstrate that 
the overshoot effect is due to the removal of the agonist per se 
rather than to a specific activity of the antagonist. 
Pretreatment of the cells with PTX, a treatment which blocks 
the opioid inhibition of AC (see Fig. 2), also blocked the nalox- 
one-induced overshoot of cAMP accumulation (Fig. 4) in the 
chronically opioid-treated cells. These results indicate that the 
overshoot phenomenon is tightly linked to the chronic activa- 
tion of the opioid receptors and to the subsequent activation 
of the PTX-sensitive Gi/Go proteins during the chronic opioid 
exposure. 
4. Discussion 
In this study, we have used CHO cell lines expressing the 
x-opioid receptor to gain information on the x-receptor signal 
transduction and its role in the opioid addictive processes. We 
have demonstrated that the x-transfected cells are able to inter- 
act with x-agonists and that this interaction leads to inhibition 
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Fig. 4. Effect of wash or antagonists on the forskolin-stimulated AC 
activity in CHO-x/8 cells chronically treated with U69593. Cells were 
treated for 4 h with 1/tM U69593. The cells were either apidly washed, 
treated for 10 min with 1/tM of the indicated antagonists (naloxone 
(Nal), n-BNI, or diprenorphine (DIP)) or washed and subsequently 
treated with the antagonists. Data are the mean + S.E.M. of three 
experiments. Significantly different from control or antagonist-treated 
cultures, *P < 0.05. 
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of the forskolin-stimulated cAMP accumulation. Several re- 
ports suggest hat activation of opioid receptors could both 
inhibit and stimulate AC activity, depending on opioid agonist 
concentration. Opioid agonists at low concentrations activate 
Gs proteins and stimulate AC activity, while high concentra- 
tions of opioid agonists activate Gi and inhibit AC activity in 
myenteric plexus and dorsal root ganglion cells [16,17]. Using 
x-opioid receptor-transfected CHO cells, we found that low 
concentrations of U69593 (e.g. as low as 0.1 riM) did not stim- 
ulate AC activity. Moreover, PTX pretreatment abolished the 
inhibitory opioid effect without unmasking any opioid activa- 
tion, suggesting that the acute opioid effects on the CHO cells 
are mediated through GJGo and not through Gs proteins. 
Long-term exposure of the transfected cells to opioids can 
offer a model system to study the molecular mechanisms of 
drug addiction and withdrawal. Using the transfected CHO cell 
lines, we have observed that the x-opioid receptors did not 
significantly desensitize following chronic opioid treatment. 
These results differ from the observations reported by Raynor 
et al. [18], who detected x-agonist-induced desensitization i  
COS-7 cells transiently transfected with the clonal mouse 
x-receptor, and from our previous results demonstrating desen- 
sitization of t0-inhibition of AC in co-cultures of spinal cord and 
dorsal root ganglion cells [2]. Moreover, these results demon- 
strate that the desensitization (or tolerance) phenomenon and 
the capacity of the cells to undergo the opioid-induced with- 
drawal or overshoot, following removal of the agonist, can be 
dissociated from each other, thus offering a cell system to study 
the overshoot phenomenon i dividually. 
Withdrawal of opioid agonists after chronic treatment (either 
by wash or the addition of an antagonist) markedly enhances 
the forskolin-stimulated cAMP accumulation. Both the fors- 
kolin-induced AC activity (without opioid treatment) and the 
overshoot activity (following chronic exposure and addition of 
naloxone) were increased as a function of forskolin concentra- 
tion (0.1-100/.tM). The ratio between the two activities was not 
affected by forskolin concentration (data not shown), suggest- 
ing that the overshoot phenomenon is not due to increased 
affinity of AC to forskolin. Since the overshoot was observed 
in the presence of IBMX (which inhibits phosphodiesterase 
activity) and was much weaker in the absence of this inhibitor 
(data not shown), it appears to result from up-regulation ofAC 
activity rather than from opioid-induced inhibition of 
phosphodiesterase. 
The degree of AC inhibition and supersensitization by
U69593 are concentration-dependent. While application of low 
concentrations of agonist were sufficient o inhibit the fors- 
kolin-stimulated cAMP production, the overshoot phenome- 
non required pretreatment with higher doses of the drug. This 
discrepancy suggests that activation of the overshoot phenom- 
enon requires threshold amounts of signaling components to 
be recruited. The nature of these signaling components remains 
to be clarified. Nevertheless, this difference in concentration is 
in agreement with the clinical observations that development 
of physical dependence requires a prolonged and high-dose 
opiate treatment [19]. 
Several cellular mechanisms could account for the overshoot 
phenomenon. The reduction in cAMP levels during the agonist 
opiate exposure could initiate a cascade of cellular changes, 
which could lead to up-regulation of the amount and/or activity 
of AC [7,20]. Enhanced coupling of the stimulatory PGEj re- 
ceptor to Gs or elevated levels of functionally intact Gs proteins 
were proposed by Ammer and Schulz [4,5] for opioid-treated 
NG108-15 and SH-SY5Y cells. Alternatively, we would like to 
suggest hat continuous release of fl)'-dimers from Gi or Go 
proteins upon prolonged activation of opioid receptors could 
eventually lead to direct or indirect activation of AC [21,22]. 
It has been claimed that in SH-SY5Y cells, naloxone blocks 
the fl-receptor activity by acting as an antagonist with negative 
intrinsic activity [23]. Our results how that the supersensitivity 
of AC is induced by the chronic agonist activation and that 
naloxone only serves as a means to remove the opioid agonism. 
Agonist wash was as effective as the application of naloxone 
or other antagonists. In spite of that, chronic agonist occupa- 
tion of the receptor per se is not sufficient o induce the with- 
drawal activation of AC. The PTX sensitivity clearly demon- 
strates that the chronic opioid activation has to be mediated 
through both opioid receptors and PTX-sensitive G proteins, 
in order to encode for the elevated cyclase activity observed 
following the agonist removal. 
In summary, using CHO cells transfected with rat x-opioid 
receptor, we have shown that acute ~c-agonist exposure leads 
to inhibition of AC, while chronic exposure leads to sensitiza- 
tion of AC activity. These observations are in line with the 
phenomenon of opiate action, addiction and withdrawal. 
Moreover, the results generalize the findings for the three dif- 
ferent types of opioid receptors and show that the overshoot 
phenomenon could be observed not only with neuronal cells 
that express the opioid receptors normally, but also with non- 
neuronal cells transfected with a defined type of opioid recep- 
tor. 
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